Company conducting first Covid-19 vaccine trial on humans says distribution can start in Fall
Today, we all look forward to receiving good news that the Covid-19 vaccine is ready to come out and save many lives including ours maybe. So, while the new type of coronavirus, which has killed at least 69 thousand people worldwide, has shaken all balances to include socio-economic one, the most curious thing about Covid-19 disease certainly seems to be when the vaccine will come out.
Moderna Therapeutics, an American firm that has tried the first vaccine against coronavirus on humans, has announced that clinical trials are continuing successfully and that the company will be able to distribute the first vaccines starting next fall.
A company official has provided important information below in regards in an interview with the press.
He said, “If governments approve, we hope to start distributing the vaccine to healthcare personnel and those at risk by the autumn of 2020” stressing that the phase of vaccine development is continuing at a “record” pace. He also noted that the second goal was to start general distribution 12 to 18 months after development began (that is in 2021) when official permits were obtained”. The official added they were preparing to produce tens of millions of vaccines every month’
Stressing that the company was capable of producing enough vaccines, the executive said, “We will have the production capacity to produce millions of vaccines every month next autumn and tens of millions in 2021. We are also preparing to make partnerships in different countries, including Europe, to enable more production”.
The executive shared following very important information as well: ‘If the coronavirus mutates, we’re ready for it, we can produce a new vaccine immediately. The virus, named SARS-Cov-2, has already mutated slightly. The method and technology we use for the vaccine focuses on proteins that are currently unaffected by ongoing mutations. But what we don’t know yet is that the mutation of this virus can also affect the proteins we target. But one of the strengths of our technology is that in the face of such a situation, we can produce new vaccine groups in just 40 days without going through clinical trials”.
SOURCE: https://tr.euronews.com
